Navigation Links
Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics' Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
Date:12/10/2007

- Company Plans to Initiate Phase IIa Study of NGX426 in Acute Migraine in

First Half of 2008 -

LA JOLLA, Calif., Dec. 10 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today reported pharmacokinetic data obtained in a Phase I maximum tolerated dose clinical trial of NGX426, the oral prodrug of tezampanel, show that the area under the curve (AUC), which represents the total amount of drug absorbed by the body, of a single, 80 mg, oral dose of NGX426 is comparable to the AUC of a single, 40 mg, subcutaneous dose of tezampanel.

With the recently demonstrated efficacy of 40 mg of tezampanel in a Phase IIb clinical trial in acute migraine, the comparable AUCs suggest that NGX426 also may be effective in treating acute migraine headache. TorreyPines Therapeutics plans to initiate a Phase IIa study of NGX426 in acute migraine in the first half of 2008.

"These findings with the oral form of tezampanel are very encouraging, especially when looked at in conjunction with the data from our evaluation of the subcutaneous form," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "These data fully support the continued development of NGX426, which, as an oral prodrug, can provide an additional route of administration for tezampanel to acute migraine sufferers."

Initiated earlier this year, this double-blind, placebo-controlled trial enrolled normal healthy adult volunteers in sequential, dose-escalating cohorts. The Phase I data show that single, oral doses of NGX426 from 40 mg to 90 mg are safe and well-tolerated. TorreyPines Therapeutics is amending the Phase I clinical trial protocol to extend the dosing range beyond 90 m
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
3. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
4. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
5. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
6. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014   Memorial Hermann Health System and ... announced a new partnership to provide a new level of ... centers in the greater Houston area. ... the exclusive provider of professional breast radiology services for five ... City, The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... Aug. 21, 2014 Nektar Therapeutics (NASDAQ: ... today announced positive results from its Phase 3 ... extended half-life recombinant factor VIII (rFVIII) treatment for ... which met its primary endpoint in reducing annualized ... to the on-demand arm. Top-line results ...
(Date:8/21/2014)... , Aug. 21, 2014 The spinal column ... the human body. Signals carried to and from the brain ... skills and nervous system. Injury or ailment here can be ... with a loss of control over their body. Though back ... a person,s life, there are more options available to make ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... CHAPEL HILL, N.C., Sept. 24 As the bio-pharmaceutical ... area of Oncology are tailoring their market education strategies ... their therapeutic area. Leading organizations have found that a ... product launch as KOLs, physicians, and payers in the ...
... WASHINGTON, Sept. 24 OrbusNeich today announced at the ... of patient enrollment in the randomized clinical trial of ... 183 patients included at sites in Asia, Australia, Europe ... this study represents a significant milestone as we look ...
Cached Medicine Technology:Effectively Educating the Marketplace to Support a Successful New Oncology Product Launch 2Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent 2Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeich's Combo™ Bio-engineered Sirolimus Eluting Stent 3
(Date:8/22/2014)... 2014 Natural Clear Vision , a ... his own vision from legally blind to perfect 20/20 vision ... review. , “There is a huge portion of the ... function, and most people just think that’s the way it ... that can be pretty risky at times,” reports Michaels. “This ...
(Date:8/22/2014)... deletion in advanced non-small cell lung cancer (NSCLC) ... in epidermal growth factor receptor (EGFR) tyrosine kinase ... BIM deletion independently predicts overall survival (OS) of ... activate the programmed cell death also known as ... been detected in 12.8% of the Asian population ...
(Date:8/22/2014)... (RA), a complex autoimmune disease that affects 1 ... not only cope with pain, disability and joint ... work, family life and marital functioning. While many ... and disability is common. In addition, some patients ... or side effects. Because of this, there is ...
(Date:8/22/2014)... London, UK (PRWEB) August 22, 2014 ... more magnetic for some clinical applications due to ... of the emerging innovations in ultrasound, such as ... imaging, are expected to keep the market moving ... as increasing mobility can enhance not only the ...
(Date:8/22/2014)... Wisconsin (PRWEB) August 22, 2014 Mueller ... for Plantar Fasciitis, an exciting new product that provides ... you to stay active while you heal. The package ... is truly a new technology – it is not ... , FasciaDerm® PFTape™ System for Plantar Fasciitis ...
Breaking Medicine News(10 mins):Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2
... BASKING RIDGE, N.J., Oct. 19 Hooper Holmes,Inc. ... a proven, standard,method for acquiring the additional health ... applicants. Mature Assessment reflects the trend of ... increased willingness to insure them.,To address these customers, ...
... Skin Treatment to Treat All ... BARRINGTON, Ill., Oct. 19 Steroids have been in ... must be reasons why,people use steroid products on a regular ... of the human body, and it needs to stay healthy. ...
... Host Conference Call and Webcast Same Afternoon, DENVER, ... of functional foods, beverages and nutritional,supplements, today announced that ... the three and nine months, ended September 30,2007, on ... a teleconference the same afternoon beginning at,4:15 PM Eastern ...
... XI,AN, China, Oct. 19 /Xinhua-PRNewswire-FirstCall/ -- Mr. Weibing ... (OTC,Bulletin Board: SKBI) ("Skystar") will be featured in ... 24, 2007, at 10:30 a.m.,EST. The interview will ... p.m. EST on,October 24. The interview will ...
... drug is given just once per month, experts say , ... treating anemia in patients with severe kidney disease could help ... , Compared with conventional therapy, giving patients an anti-anemia drug ... concluded Dr. Nathan Levin, of the Renal Research Institute in ...
... ... at TCT 2007 ... Oct. 19 Stereotaxis, Inc. (Nasdaq:,STXS) announced today that it will ... at the,Transcatheter Cardiovascular Therapeutics (TCT) symposium in Washington,D.C., October 20 to ...
Cached Medicine News:Health News:Hooper Holmes Introduces Mature Assessment 2Health News:Steroids Are Abused for Skin, Not Just Muscles 2Health News:XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007 2Health News:XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007 3Health News:Skystar Bio-Pharmaceutical Announces Upcoming Interview With WallSt.net ( www.wallst.net ) 2Health News:Simpler Anemia Treatment May Help Kidney Patients 2Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 2Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 3Health News:Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: